6 Supplements to Avoid on Retatrutide (Doctor Explains) #retatrutide #glp1

Main ideas / lessons

• Retatrutide basics & why supplements matter

  • Retatrutide is a triple agonist that acts on GIP, GLP-1, and glucagon receptors.
  • The video focuses on the glucagon arm, described as the “secret sauce” that drives a persistent liver fuel-release state, including:
    • increased glycogen breakdown
    • increased glucose production
    • increased fat oxidation
  • The speaker outlines “collisions” where supplements could interfere (or worsen risk), framed by three possible pathways:
    1. Liver collision: glucagon-driven fat oxidation + rapid weight loss → increased fatty-acid flux to the liver; supplements with liver-toxicity/oxidation concerns may be especially risky.
    2. Heart collision: the glucagon pathway is described as increasing heart rate/contractility via cardiac glucagon receptors (not via an adrenaline pathway).
    3. Ketone pathway collision: glucagon may increase ketone production via increased fat oxidation and glucose/oxaloacetate effects; supplements that push ketones could become problematic.

• Safety framing

  • Retatrutide is not FDA-approved yet (at the time of the talk, it is still in phase 3 trials) → the content is educational.
  • The speaker emphasizes speaking with a physician before changing anything.
  • He states there are no randomized studies directly testing supplement interactions with retatrutide; his conclusions are biochemistry-based hypotheses.
  • A “five-alarm” severity scale is used:
    • 5-alarm fire = potential worst-case serious medical harm
    • 1-alarm = minor inconvenience

• Overall thesis

  • The listed supplements have limited standalone benefit for weight loss compared with retatrutide.
  • Because of potential mechanism-based risks (liver/heart/ketones), the speaker argues you should avoid or set aside these supplements while on retatrutide.

---

Methodology / list of supplements to avoid (detailed)

1) Green tea extract (rated 5-alarm, mainly liver risk)

• Why avoid (mechanism/risk):
  • Green tea catechins—especially EGCG—are described as a leading cause of supplement-induced liver injury in the US (citing a USP expert panel).
  • Liver injury risk is linked to EGCG dose; cases start around ~140 mg/day EGCG.
  • Typical thermogenic use may deliver ~200–500 mg EGCG.
  • Retatrutide may increase vulnerability via three factors:
    1. Faster EGCG uptake while fasting: fasting increases EGCG absorption; retatrutide may cause people to skip meals.
    2. Caloric restriction effect: EGCG is described as causing liver injury in mice under caloric restriction (even if not under normal feeding).
    3. Glucagon-arm increases hepatic fat oxidation: the metabolic state may “arrive at a bad time” for hepatotoxic compounds.
• Additional contextual point:
  • Brewed tea is implied to be lower-risk than concentrated extracts because exposure is slower and lower.
  • Labels can be hard to interpret due to proprietary blends that may not allow exact EGCG dosing.
• Verdict: Stop / strong avoid.

---

2) Yohimbine (rated 5-alarm, mainly heart risk)

• Why avoid (mechanism/risk):
  • Yohimbine is described as blocking alpha-2 adrenergic receptors, removing inhibition of norepinephrine release → potential for:
    • high blood pressure
    • fast heart rate
    • anxiety, tremors, sweating
  • Combined with retatrutide’s glucagon-driven direct cardiac stimulation, the two effects are portrayed as stacking toward excessive cardiac stimulation through different pathways.
• Product quality/dosing unpredictability:
  • A testing claim: many retail products had inaccurate labeling; actual yohimbine content ranged widely (including batches far above or below label claims).
  • Because the dose is unreliable, the speaker argues no dose is clearly safe.
• Benefit side described as underwhelming:
  • A small study is mentioned where body fat reduction occurred without major changes in performance/body/muscle metrics.
• Verdict: Strong stop / strong avoid.

---

3) MCT oil (rated 3-alarm, ketone-pathway risk)

• Why avoid (mechanism/risk):
  • MCTs (C8/C10) are described as going more directly into liver metabolism:
    • entering portal circulation
    • reaching mitochondria without the carnitine shuttle
    • rapidly increasing acetyl-CoA, which can be shunted toward ketone body production
  • Retatrutide’s glucagon arm is described as driving glucose production that uses up oxaloacetate, leaving acetyl-CoA shunted toward ketones.
• Two potential problems:
  1. GI intolerance: doses above ~20 g at once can cause cramping/diarrhea (could derail adherence).
  2. Potentially life-threatening ketone excess: if ketone production outpaces clearance → ketoacidosis risk, especially with vomiting or deliberate low-carb intake—situations that can occur on retatrutide.
• Important uncertainty stated:
  • The speaker says it’s not known whether therapeutic retatrutide raises ketones in humans (no clear published ketone endpoints were referenced).
• Verdict: Set aside, especially if actively losing weight on retatrutide or following a low-carb diet.

---

4) Berberine (rated 3-alarm, liver collision in “the other direction” + interaction concerns)

• Why avoid (mechanism/risk):
  • The speaker calls berberine effective overall (especially for glycemic control), citing a meta-analysis in type 2 diabetes with meaningful:
    • A1C
    • fasting glucose
    • BMI reductions
  • Two major caveats are raised:
    • publication bias (traditional medicine trials; limited databases)
    • possible data handling/sign errors in reported cholesterol confidence intervals, reducing confidence.
• Interaction with retatrutide’s glucagon arm:
  • Berberine inhibits mitochondrial complex 1 → activates AMPK → suppresses hepatic glucose production (similar lever to metformin).
  • Since retatrutide’s glucagon pathway stimulates hepatic glucose production, berberine is described as partially antagonizing the glucagon-driven effect, making net glucose effects unpredictable.
• Compounding GI side effects:
  • Both can cause GI upset, potentially reducing tolerance and ability to reach ideal dosing.
• Verdict: Avoid / set aside despite glucose benefits, due to interaction uncertainty and additive side effects.

---

5) Bitter orange (p-synephrine) (rated 2-alarm, heart pathway; caution about combination products)

• Why avoid (mechanism/risk):
  • Synephrine is described as replacing ephedra in thermogenics after regulatory bans.
  • Crossover studies are referenced suggesting synephrine alone may not significantly raise HR/BP at certain doses.
• Reasons for caution despite weak evidence for isolated synephrine:
  • The speaker claims product behavior differs from the molecule:
    • people typically take bitter orange + caffeine (and sometimes theacrine)
  • Retatrutide already raises resting heart rate via the glucagon arm, so adding caffeine stacks could increase cardiac strain.
  • He also points to potential bias in studies and differences in study design.
• Instruction (important nuance):
  • The takeaway is not simply “avoid synephrine,” but to:
    • read the whole supplement panel
    • check caffeine content
    • check whether yohimbine or hordenine is included
• Verdict: Use real caution based on the product stack, especially caffeine and related stimulants.

---

6) L-carnitine (rated 1-alarm, mainly TMAO/atherosclerosis hypothesis)

• Why avoid (mechanism/risk):
  • L-carnitine increases the fatty-acid shuttle, enabling long-chain fat entry into mitochondria.
  • Retatrutide’s glucagon arm is described as already lowering malonyl-CoA and opening that “gate,” so additional carnitine may augment metabolic flux (even if it is not usually the rate-limiting step in people who are well nourished).
• Key concern: TMAO
  • Gut microbes convert L-carnitine into TMAO, linked to atherosclerosis.
  • The link is described as:
    • observational (not fully causal)
    • possibly confounded by “healthy user bias” and reverse causation
    • but supported by mechanistic plausibility
  • Specific uncertainty for retatrutide: the speaker says incretin therapy can shift the gut microbiome, so conversion to TMAO under retatrutide may differ.
• Verdict: Avoid, but categorized as lower severity than the others.

---

Comparative effectiveness / wrap-up

• The speaker emphasizes none of these supplements produce impressive weight loss on their own.
• The cited weight effects for the supplements are small (about ~1.2–1.3 kg) compared with retatrutide (described as ~24.2% weight loss in the referenced trial context).
• Final recommendation: set these supplements aside (or don’t buy them).

---

Speakers / sources featured

• Speaker: Dr. Cleve Barric (founder of Barric Health; board certified in internal medicine and obesity medicine)

• Referenced/quoted sources (mentioned in the video):

  • FDA (approval status; not yet approved)
  • USP Expert Panel (green tea extract as leading cause of supplement-induced liver injury—claimed)
  • Retatrutide clinical trial program, including:
    • Phase 2 obesity trial (338 patients, 48 weeks; weight-loss figures mentioned)
    • Phase 2 liver sub-study (liver fat reductions mentioned)
  • Minnesota Green Tea trial (women; EGCG vs placebo; genotype/ALT changes mentioned)
  • A study on yohimbine product labeling accuracy (49 products, 7 retailers; mislabeled/variable content claim)
  • A meta-analysis in type 2 diabetes for berberine (46 randomized trials; outcomes and caveats mentioned)
  • Crossover studies on bitter orange/p-synephrine and cardiovascular measures
  • Observational research linking TMAO to atherosclerosis (causality not established; confounding noted)